{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen HY"],"funding":["Innovative Research Group Project of the National Natural Science Foundation of China"],"pagination":["33"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7879534"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["<h4>Background</h4>Although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard chemotherapy regimen for diffuse large B cell lymphoma (DLBCL) patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment response.<h4>Methods</h4>We utilized 5hmC-Seal to generate genome-wide 5hmC profiles in plasma cell-free DNA (cfDNA) from 86 DLBCL patients before they received R-CHOP chemotherapy. To investigate the correlation between 5hmC modifications and curative effectiveness, we separated patients into training (n = 56) and validation (n = 30) cohorts and developed a 5hmC-based logistic regression model from the training cohort to predict the treatment response in the validation cohort.<h4>Results</h4>"],"journal":["Clinical epigenetics"],"pubmed_title":["5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients."],"pmcid":["PMC7879534"],"funding_grant_id":["81800195","31471299","81522046"],"pubmed_authors":["Liu H","Liu J","Xu N","He C","Li F","Chen L","Qin Y","Zhang L","Wang J","Li W","Xiao XB","Hong Y","He XH","Zhu HC","Chen HY","Yang P","Yang ZR","Pang M","Yan C","Jing HM","Lin J","Zhang WL"],"additional_accession":[]},"is_claimable":false,"name":"5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.","description":"<h4>Background</h4>Although R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard chemotherapy regimen for diffuse large B cell lymphoma (DLBCL) patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment response.<h4>Methods</h4>We utilized 5hmC-Seal to generate genome-wide 5hmC profiles in plasma cell-free DNA (cfDNA) from 86 DLBCL patients before they received R-CHOP chemotherapy. To investigate the correlation between 5hmC modifications and curative effectiveness, we separated patients into training (n = 56) and validation (n = 30) cohorts and developed a 5hmC-based logistic regression model from the training cohort to predict the treatment response in the validation cohort.<h4>Results</h4>","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2026-05-04T18:27:20.384Z","creation":"2021-02-21T10:46:59Z"},"accession":"S-EPMC7879534","cross_references":{"pubmed":["33573703"],"doi":["10.1186/s13148-020-00973-8"]}}